Shiitake

Metadata

Regulatory Status

European Regulatory Bodies

• Commission E (Germany): No monograph exists. Shiitake was not part of the European herbal tradition assessed by Commission E.
• ESCOP: No monograph.
• EMA/HMPC: No assessment report or monograph. Lentinula edodes is not in the EU Community Herbal Monograph program.

Novel Food (EU)

Shiitake is not classified as a Novel Food in the EU. It has an established history of consumption in Europe as a culinary mushroom and is widely available in European food markets. This exempts the whole mushroom from Novel Food requirements, though novel concentrated extracts or isolated compounds (such as lentinan) intended for medicinal use may face different regulatory pathways.

Chinese Pharmacopoeia

Shiitake (Xiang Gu) is listed in the Chinese Pharmacopoeia. Traditional TCM indications include strengthening the spleen and stomach, supplementing qi, promoting appetite, and supporting immune function. It has been a prized culinary and medicinal mushroom in China since at least the Song Dynasty (960-1279 CE), with the earliest cultivation methods attributed to Wu San Kwung during the Southern Song period.

Japanese Approval — Lentinan

Lentinan is approved in Japan as an injectable biological response modifier (BRM) for adjunctive treatment of gastric cancer. This approval, granted in 1985, is based on clinical trial data demonstrating improved survival when lentinan is administered intravenously in combination with tegafur-based chemotherapy regimens. Lentinan is marketed in Japan under the trade name Lentinan (Ajinomoto) and has been administered to tens of thousands of cancer patients since approval. This makes lentinan one of only three mushroom-derived compounds approved as anti-cancer adjunctive therapy in Japan (alongside PSK from turkey tail and schizophyllan from Schizophyllum commune).

Korean Traditional Medicine

Shiitake (Pyogo) is recognized in Korean traditional medicine and is one of the most widely consumed medicinal mushrooms in Korea. Korean research has contributed significantly to understanding shiitake’s immunological and nutritional properties.

United States

• FDA GRAS status: Shiitake mushroom is generally recognized as safe (GRAS) as a food ingredient.
• Dietary supplement: Shiitake extracts are widely available as dietary supplements under DSHEA.
• AHCC (Active Hexose Correlated Compound): A proprietary extract derived from shiitake mycelium culture is one of the best-selling immune supplements in Japan and is marketed as a dietary supplement in the US with a substantial body of clinical research.
• Lentinan is not FDA-approved as a drug in the United States.

Conditions & Indications

Primary (Strong Evidence)

Gastric Cancer — Adjunctive Therapy (Lentinan, Injectable)

This is the indication with the strongest clinical evidence, supported by multiple RCTs and meta-analyses:

• Oba et al. (2009) published a meta-analysis of three RCTs (n=650) evaluating intravenous lentinan combined with tegafur-based chemotherapy in advanced/recurrent gastric cancer. The combined analysis demonstrated a statistically significant improvement in overall survival (HR 0.80, 95% CI 0.66-0.97, p=0.03), corresponding to a 20% reduction in the hazard of death.
• Ina et al. (2013) reported that lentinan combined with S-1 (tegafur/gimeracil/oteracil) chemotherapy significantly improved median survival time (MST) compared to S-1 alone in unresectable or recurrent gastric cancer patients.
• Wang et al. (2012) conducted a meta-analysis of lentinan combined with chemotherapy for gastric and colorectal cancer, finding improved overall response rates and reduced adverse effects of chemotherapy.

Immune Function Enhancement (Oral Shiitake)

• Dai et al. (2015) conducted a randomized, parallel-group trial in 52 healthy young adults consuming 5 or 10 g of dried shiitake daily for 4 weeks. Results showed increased ex vivo proliferation of gamma-delta T-cells and NK-T cells, increased secretory IgA production, reduced C-reactive protein (CRP), and altered cytokine patterns consistent with enhanced immune surveillance and reduced systemic inflammation.
• AHCC supplementation has been studied in multiple clinical trials for immune function, with evidence of enhanced NK cell activity and cytokine production in cancer patients and healthy volunteers.

Secondary (Moderate Evidence)

Cholesterol Reduction

• Eritadenine, a unique compound found almost exclusively in shiitake, lowers plasma cholesterol in animal models at oral doses as low as 5 mg/kg in rats (Enman et al., 2007). The mechanism involves inhibition of S-adenosylhomocysteine hydrolase (SAHH), which modulates phosphatidylcholine biosynthesis in the liver and shifts cholesterol toward biliary excretion.
• Dietary shiitake consumption (as food) has been associated with modest cholesterol reductions in several small human studies, including Wasser (2005), though large-scale RCTs are lacking.
• Rahman et al. (2024) demonstrated in a controlled feeding trial that incorporation of shiitake into the diet reduced LDL cholesterol compared to control diets.

HPV Clearance (AHCC)

• Smith et al. (2019) published a pilot randomized trial of AHCC supplementation in women with persistent HPV infection. AHCC supplementation (3 g/day for 6 months) supported HPV clearance in a subset of patients, with durable responses at 6-month follow-up. A confirmatory Phase II trial has been completed with results supporting AHCC’s role in supporting immune clearance of HPV (Smith et al., 2022).

Emerging/Preclinical

• Anti-viral activity: Lentinan and shiitake polysaccharides demonstrate anti-viral activity against influenza, HIV, herpes simplex, and hepatitis B in in vitro and animal models. The mechanism is indirect (immune-mediated) rather than direct antiviral activity.
• Hepatoprotection: Shiitake polysaccharides protect against liver injury in animal models of hepatotoxicity, with proposed mechanisms including antioxidant activity, NF-kB inhibition, and hepatocyte regeneration promotion.
• Oral health: Shiitake extract has demonstrated anti-biofilm activity against oral pathogens and reduced gingivitis markers in a small pilot study.

Mechanism of Action

1. Lentinan — Beta-Glucan Immune Activation

Lentinan is a high-molecular-weight (approximately 500 kDa) beta-1,3-glucan with beta-1,6 side chains, extracted from shiitake fruiting body cell walls. Its triple-helix tertiary structure is essential for biological activity:

• Dectin-1 receptor binding: Lentinan is recognized by Dectin-1 (CLEC7A) on macrophages, dendritic cells, and neutrophils. This binding activates Syk kinase and downstream CARD9-BCL10-MALT1 signaling, leading to NF-kB activation and pro-inflammatory cytokine production.
• Complement receptor 3 (CR3): Lentinan fragments also bind CR3 (CD11b/CD18) on neutrophils and NK cells, priming them for enhanced cytotoxicity against iC3b-opsonized target cells.
• T-cell modulation: Lentinan promotes Th1-polarized immune responses, increasing IFN-gamma and IL-12 production while suppressing IL-4 and IL-10 (Th2 cytokines). This shifts the immune balance toward cell-mediated anti-tumor immunity.
• Complement activation: Lentinan activates the complement system through the alternative pathway, generating C3a and C5a anaphylatoxins that enhance immune cell recruitment and opsonization.
• Host-mediated anti-tumor activity: Lentinan does not kill tumor cells directly. Its anti-cancer effect is entirely mediated through enhancement of the host immune system’s ability to recognize and destroy tumor cells. This distinguishes it from conventional cytotoxic chemotherapy.

2. Eritadenine — Cholesterol Metabolism

Eritadenine (2(R),3(R)-dihydroxy-4-(9-adenyl)-butyric acid) is an adenosine analog found almost exclusively in Lentinula edodes:

• SAHH inhibition: Eritadenine inhibits S-adenosylhomocysteine hydrolase (SAHH), the enzyme that catalyzes the reversible hydrolysis of S-adenosylhomocysteine (SAH) to homocysteine and adenosine. SAHH inhibition increases intracellular SAH, which in turn inhibits phosphatidylethanolamine N-methyltransferase (PEMT), the enzyme responsible for converting phosphatidylethanolamine to phosphatidylcholine in the liver.
• Downstream cholesterol effects: Reduced hepatic phosphatidylcholine synthesis alters VLDL assembly and secretion, shifts cholesterol toward biliary excretion, and results in lower circulating LDL cholesterol. This mechanism is distinct from statins (HMG-CoA reductase inhibition) and represents a unique pharmacological approach to cholesterol lowering.
• Potency: Eritadenine is active at remarkably low oral doses in rats (5 mg/kg), suggesting high potency relative to whole mushroom consumption.

3. Ergothioneine — Cellular Antioxidant

Ergothioneine (EGT) is a sulfur-containing amino acid biosynthesized by fungi but not by humans. Shiitake is one of the richest dietary sources:

• OCTN1 transporter: Humans express a specific ergothioneine transporter (OCTN1/SLC22A4) in tissues with high oxidative stress (red blood cells, liver, kidney, eyes, bone marrow), suggesting an evolved physiological role for this dietary compound.
• Antioxidant mechanism: Ergothioneine scavenges hydroxyl radicals, hypochlorous acid, and singlet oxygen more efficiently than glutathione at physiological pH. It chelates divalent metal ions (Cu2+, Fe2+), preventing Fenton chemistry-mediated radical generation.
• Mitochondrial protection: Ergothioneine accumulates in mitochondria and protects against oxidative damage to mitochondrial DNA and electron transport chain components.

4. Lenthionine — Antiplatelet Activity

Lenthionine (1,2,3,5,6-pentathiepane) is the sulfur compound responsible for shiitake’s distinctive aroma. It demonstrates antiplatelet activity through inhibition of platelet aggregation induced by collagen, ADP, and arachidonic acid, with a mechanism involving suppression of thromboxane A2 synthesis.

Clinical Evidence Summary

Meta-Analyses and Systematic Reviews

Key Randomized Controlled Trials

The Oba et al. (2009) Meta-Analysis — Detailed Analysis

This is the most rigorous assessment of lentinan’s clinical efficacy:

• Population: 650 patients with advanced or recurrent gastric cancer across three Japanese RCTs
• Intervention: Intravenous lentinan (2 mg, typically twice weekly) combined with tegafur-based oral fluoropyrimidine chemotherapy
• Comparator: Tegafur-based chemotherapy alone
• Primary outcome: Overall survival
• Result: HR 0.80 (95% CI 0.66-0.97), indicating a 20% reduction in the risk of death with lentinan combination therapy
• Clinical significance: This is a statistically and clinically meaningful survival benefit in advanced gastric cancer, a disease with poor prognosis. The magnitude of benefit is comparable to many approved oncology drugs.
• Limitations: All three RCTs were conducted in Japan; generalizability to non-Japanese populations is uncertain; open-label design in individual trials; potential confounding from differences in supportive care.

Evidence Strengths and Limitations

Strengths:

• Lentinan has the strongest evidence base of any mushroom-derived compound, with regulatory approval in Japan based on RCT data
• The Oba meta-analysis demonstrates a statistically significant survival benefit in a well-defined cancer population
• The Dai et al. (2015) trial provides controlled human evidence for immune modulation from dietary shiitake consumption
• AHCC has a substantial and growing clinical evidence base, particularly for HPV and immune function

Limitations:

• All pivotal lentinan RCTs were conducted in Japan; cross-cultural validation is needed
• Lentinan requires intravenous administration; oral shiitake supplements deliver a different pharmacological profile
• AHCC is a proprietary mycelium-culture extract distinct from whole shiitake; results are not generalizable to standard shiitake products
• Eritadenine’s cholesterol-lowering effect is well-characterized mechanistically but lacks large-scale human RCT confirmation

Safety Profile

General Assessment

Shiitake has been consumed as a staple culinary mushroom across East Asia for over a millennium and is widely consumed worldwide. The whole mushroom has an excellent safety profile as a food. Lentinan injectable has been administered to tens of thousands of cancer patients in Japan with a well-characterized adverse event profile. AHCC has demonstrated a favorable safety profile across multiple clinical trials.

Drug Interactions

Shiitake Dermatitis

A distinctive adverse reaction unique to shiitake:

• Flagellate erythema (shiitake flagellate dermatitis): Consumption of raw or undercooked shiitake can trigger a characteristic linear, whip-like erythematous skin rash, typically appearing 24-48 hours after ingestion and resolving spontaneously within 1-3 weeks.
• Mechanism: Attributed to lentinan, which at high concentrations triggers IL-1 secretion and direct vasodilation. The flagellate pattern may relate to Koebner-like mechanical sensitization.
• Prevention: Thorough cooking (at least 15-20 minutes) denatures lentinan and prevents this reaction. The condition occurs almost exclusively from raw or briefly cooked mushroom consumption.
• Incidence: Uncommon but well-documented in the dermatology literature with hundreds of case reports, predominantly from Japan and increasingly from Western countries as raw shiitake consumption becomes more common.

Lentinan Injectable — Adverse Effects

• Common: Injection site reactions, mild fever, chills (related to immune activation)
• Uncommon: Anaphylaxis (rare), liver enzyme elevation, leukopenia
• Monitoring: Standard oncology monitoring protocols apply; periodic liver function tests and complete blood counts are recommended during lentinan therapy

Contraindications

• Autoimmune conditions: Immunostimulatory beta-glucans may exacerbate autoimmune disease activity
• Organ transplant recipients: Immune activation from lentinan or concentrated shiitake extracts may counteract immunosuppressive therapy and increase rejection risk
• Known shiitake allergy: Individuals with documented shiitake allergy or history of shiitake flagellate dermatitis should avoid all shiitake products

Pregnancy and Lactation

Shiitake consumed as a culinary food is considered safe during pregnancy and has been consumed by pregnant women in East Asia for centuries without documented adverse effects. However, concentrated medicinal extracts (lentinan injectable, AHCC, high-dose polysaccharide preparations) lack specific reproductive safety data and should be avoided during pregnancy and lactation as a precautionary measure.

Clinical Dosage

Culinary Consumption

• Dietary dose: 5-10 g dried shiitake daily (approximately 50-100 g fresh weight)
• Dai et al. (2015) protocol: 5 or 10 g dried shiitake mushrooms daily for 4 weeks, reconstituted and cooked before consumption
• Important: Mushrooms must be thoroughly cooked to prevent flagellate dermatitis and to improve digestibility and bioactive release

Lentinan Injectable (Japan — Approved Indication)

• Standard oncology dose: 2 mg administered intravenously, typically twice weekly
• Administration: Intravenous infusion in combination with fluoropyrimidine-based chemotherapy (S-1 or tegafur/uracil)
• Duration: Continued until disease progression or intolerable toxicity
• This is a prescription pharmaceutical, not a dietary supplement, and requires oncologist supervision

Shiitake Extract (Oral Supplement)

• Standard dose: 1-3 g/day of dried shiitake extract, typically standardized to polysaccharide or beta-glucan content
• Hot-water extraction is preferred for polysaccharide bioavailability
• Products should specify beta-glucan content through validated testing; a minimum of 20% beta-glucans indicates reasonable quality

AHCC (Active Hexose Correlated Compound)

• Standard dose: 1-3 g/day in divided doses
• Smith et al. (2019) HPV protocol: 3 g/day for 6 months
• AHCC is a proprietary preparation from cultured shiitake mycelium (not fruiting body); it is distinct from standard shiitake supplements and has its own evidence base

Eritadenine Considerations

• Eritadenine content in dried shiitake is approximately 3-6 mg per gram of dried mushroom
• At a dietary dose of 10 g dried shiitake, the eritadenine intake would be approximately 30-60 mg, which is within the range shown to have cholesterol-lowering effects in animal dose-equivalence calculations
• No isolated eritadenine supplement is commercially available; cholesterol effects from shiitake require consistent dietary consumption or fortified extracts

Sources

• Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J. Individual patient based meta-analysis of lentinan for unresectable/recurrent gastric cancer. Anticancer Res. 2009;29(7):2739-2745
• Ina K, Kataoka T, Ando T. The use of lentinan for treating gastric cancer. Anticancer Agents Med Chem. 2013;13(5):681-688
• Wang H, Cai Y, Zheng Y, Bai Q, Xie D, Yu J. Efficacy of biological response modifier lentinan with chemotherapy for advanced cancer: a meta-analysis. Cancer Med. 2012;1(2):59-68
• Hazama S, Watanabe S, Ohashi M, et al. Efficacy of orally administered superfine dispersed lentinan (beta-1,3-glucan) for the treatment of advanced colorectal cancer. Anticancer Res. 2009;29(7):2611-2617
• Dai X, Stanilka JM, Rowe CA, et al. Consuming Lentinula edodes (shiitake) mushrooms daily improves human immunity: a randomized dietary intervention in healthy young adults. J Am Coll Nutr. 2015;34(6):478-487
• Smith JA, Mathew L, Gaikwad A, et al. From bench to bedside: evaluation of AHCC supplementation to modulate the host immunity to clear high-risk human papillomavirus infections. Front Oncol. 2019;9:173
• Smith JA, Gaikwad A, Mathew L, et al. AHCC supplementation to support immune function to clear persistent human papillomavirus infections. Front Oncol. 2022;12:922696
• Enman J, Rova U, Berglund KA. Quantification of the bioactive compound eritadenine in selected strains of shiitake mushroom (Lentinus edodes). J Agric Food Chem. 2007;55(4):1177-1180
• Halliwell B, Cheah IK, Tang RMY. Ergothioneine — a diet-derived antioxidant with therapeutic potential. FEBS Lett. 2018;592(20):3357-3366
• Cheah IK, Halliwell B. Ergothioneine, recent developments. Redox Biol. 2021;42:101868
• Wasser SP. Shiitake (Lentinus edodes). In: Encyclopedia of Dietary Supplements. 2005:653-664
• Rahman MA, et al. Dietary mushroom intake and cardiovascular risk factors: a controlled feeding trial. Nutr Metab Cardiovasc Dis. 2024;34(3):612-620
• Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K. A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Hepatogastroenterology. 1999;46(28):2662-2668
• Zhang M, Kim JA, Huang AYC. Optimizing natural killer cell-based cancer immunotherapy with AHCC. J Ginseng Res. 2018;42(3):339-345
• Bisen PS, Baghel RK, Sanodiya BS, Thakur GS, Prasad GB. Lentinus edodes: a macrofungus with pharmacological activities. Curr Med Chem. 2010;17(22):2419-2430
• Chihara G, Maeda Y, Hamuro J, Sasaki T, Fukuoka F. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing. Nature. 1969;222(5194):687-688

Connections

• Compare with Maitake — both are prized Japanese culinary mushrooms with immunomodulatory polysaccharides; maitake D-fraction targets a similar niche but lacks the regulatory approval and RCT volume that lentinan has achieved
• Compare with Turkey Tail — PSK from turkey tail is the other major mushroom-derived approved anti-cancer adjuvant in Japan; PSK and lentinan represent the two strongest examples of mushroom immunotherapy achieving pharmaceutical validation
• Compare with Reishi — reishi has broader pharmacological activity (triterpenoids + polysaccharides) but does not have a compound approved as a pharmaceutical drug; shiitake’s lentinan represents a higher level of clinical validation
• Shiitake’s eritadenine mechanism (SAHH inhibition affecting phospholipid metabolism) is entirely unique among medicinal mushrooms and unrelated to the statin mechanism, representing a novel pharmacological approach to cholesterol management
• Ergothioneine from shiitake connects to the broader antioxidant-longevity theme — humans express a dedicated transporter (OCTN1) for this fungal compound, suggesting an evolved dietary relationship between humans and mushrooms
• The AHCC evidence base for HPV clearance represents an emerging clinical application that bridges mycotherapy and infectious disease immunology
• Shiitake flagellate dermatitis, while uncommon, is a clinically distinctive adverse reaction that serves as a reminder that even well-established food mushrooms can produce unexpected pharmacological effects from specific bioactive compounds (lentinan in this case)